Rakovina Therapeutics Reports 2024 Financial Results

Rakovina Therapeutics Inc. (TSX-V: RKV, FSE: 7JO), a biopharmaceutical company developing cancer therapies using artificial intelligence, has announced its financial results for the fourth quarter and fiscal year ending December 31, 2024, alongside a corporate update.

The company announced its intention to appoint Yevgeniy Meshcherekov and David Kideckel to its board of directors, subject to TSX Venture Exchange approval. Michael Liggett has retired from the board, and Meshcherekov is expected to succeed him as chair of the audit committee.

During 2024, Rakovina Therapeutics advanced its drug discovery programs, presenting preclinical data for its kt-2000 and kt-5000 programs at the AACR annual meeting. These data suggest that candidates from its AI collaborations may meet target product profiles for a PARP-1 selective lead candidate (kt-2000) and an ATR inhibitor (kt-5000). The company also reported receiving the first synthesized ATR inhibitor compounds from its collaboration with Variational AI in March 2025.

The company secured $5 million in private placements during 2024 to fund its research and development initiatives. In January 2025, Rakovina Therapeutics listed its common shares on the Frankfurt Stock Exchange (FSE) under the ticker symbol "7J0." The company also expanded its collaborations with the University of British Columbia and Pharma Inventor Inc. to bolster its AI drug discovery efforts. Rakovina Therapeutics continues to focus on its AI-driven pipeline, aiming to deliver novel therapeutic options for cancer patients.